Personalised Neoantigen Immunotherapy – Demonstrating Priming of CD8+ T cell Responses is a Key Step

Time: 9:15 am
day: Day One


• Typical solid tumor epithelial cells display class I HLA-presented neoantigens (not class II)
• Consistent priming of strong CD8+ T cell responses to these neoantigens is likely key to effective immunotherapy
• We will show phase one clinical and immunogenicity data from a heterologous prime-boost neoantigen immunotherapy program in solid tumor patients